Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1987 Nov;92(3):479–481. doi: 10.1111/j.1476-5381.1987.tb11346.x

Effect of angiotensin-converting enzyme inhibitor YS980 on prostaglandin synthesis in rabbit kidney medulla slices.

Y Fujimoto 1, K Wada 1, M Kaneko 1, T Fujita 1
PMCID: PMC1853692  PMID: 3480765

Abstract

The effect of YS980, an angiotensin-converting enzyme inhibitor, on the generation of medullary prostaglandins E2 and F2 alpha was examined. At concentrations of 0.2 mM and below, YS980 enhanced prostaglandin F2 alpha synthesis at the expense of prostaglandin E2. At concentrations of 0.4 mM or more, YS980 inhibited synthesis of both prostaglandins E2 and F2 alpha markedly. These results suggest that YS980 has the potential to modulate prostaglandins E2 and F2 alpha synthesis by the kidney and that this effect may represent some pharmacological action of the drug.

Full text

PDF
479

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cushman D. W., Cheung H. S., Sabo E. F., Ondetti M. A. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry. 1977 Dec 13;16(25):5484–5491. doi: 10.1021/bi00644a014. [DOI] [PubMed] [Google Scholar]
  2. Dorer F. E., Kahn J. R., Lentz K. E., Levine M., Skeggs L. T. Hydrolysis of bradykinin by angiotensin-converting enzyme. Circ Res. 1974 Jun;34(6):824–827. doi: 10.1161/01.res.34.6.824. [DOI] [PubMed] [Google Scholar]
  3. Erdös E. G. Conversion of angiotensin I to angiotensin II. Am J Med. 1976 May 31;60(6):749–759. doi: 10.1016/0002-9343(76)90889-5. [DOI] [PubMed] [Google Scholar]
  4. Flower R. J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974 Mar;26(1):33–67. [PubMed] [Google Scholar]
  5. Fujimoto Y., Fujita T. Effects of lipid peroxidation on prostaglandin synthesis in rabbit kidney medulla slices. Biochim Biophys Acta. 1982 Jan 15;710(1):82–86. [PubMed] [Google Scholar]
  6. Fujimoto Y., Tanioka H., Keshi I., Fujita T. The interaction between lipid peroxidation and prostaglandin synthesis in rabbit kidney-medulla slices. Biochem J. 1983 Apr 15;212(1):167–171. doi: 10.1042/bj2120167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fujita T., Yamamoto T., Tabata M., Ueno T., Fujimoto Y. The effects of reduced glutathione and cysteine on prostaglandin synthesis in rabbit kidney medulla slices. Comp Biochem Physiol C. 1986;83(1):29–31. doi: 10.1016/0742-8413(86)90008-3. [DOI] [PubMed] [Google Scholar]
  8. Hamberg M., Samuelsson B. Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc Natl Acad Sci U S A. 1973 Mar;70(3):899–903. doi: 10.1073/pnas.70.3.899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hamberg M., Svensson J., Wakabayashi T., Samuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci U S A. 1974 Feb;71(2):345–349. doi: 10.1073/pnas.71.2.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Iso T., Yamauchi H., Suda H., Nakajima N., Nishimura K., Iwao J. Potentiative effects of sulfhydryl compounds on carrageenin-induced oedema in rats and relationship to their potencies as inhibitors of angiostin-coverting enzyme in vivo. Experientia. 1978 Sep 15;34(9):1202–1203. doi: 10.1007/BF01922957. [DOI] [PubMed] [Google Scholar]
  11. Mita I., Iwao J., Oya M., Chiba T., Iso T. New sulfhydryl compounds with potent antihypertensive activities. Chem Pharm Bull (Tokyo) 1978 Apr;26(4):1333–1335. doi: 10.1248/cpb.26.1333. [DOI] [PubMed] [Google Scholar]
  12. Miyamoto T., Ogino N., Yamamoto S., Hayaishi O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem. 1976 May 10;251(9):2629–2636. [PubMed] [Google Scholar]
  13. Nugteren D. H., Hazelhof E. Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biophys Acta. 1973 Dec 20;326(3):448–461. doi: 10.1016/0005-2760(73)90145-8. [DOI] [PubMed] [Google Scholar]
  14. Ondetti M. A., Rubin B., Cushman D. W. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977 Apr 22;196(4288):441–444. doi: 10.1126/science.191908. [DOI] [PubMed] [Google Scholar]
  15. Tobian L., O'Donnell M. Renal prostaglandins in relation to sodium regulation and hypertension. Fed Proc. 1976 Oct;35(12):2388–2392. [PubMed] [Google Scholar]
  16. Van der Ouderaa F. J., Buytenhek M., Nugteren D. H., Van Dorp D. A. Purification and characterisation of prostaglandin endoperoxide synthetase from sheep vesicular glands. Biochim Biophys Acta. 1977 May 25;487(2):315–331. doi: 10.1016/0005-2760(77)90008-x. [DOI] [PubMed] [Google Scholar]
  17. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES